Hepatitis C, HIV, HIV-HCV Coinfection
Conditions
Keywords
Interferon-free, Direct acting antiviral (DAA), Treatment as prevention, Surveillance, Feasibility
Brief summary
The purpose of this study is to evaluate the feasibility of rapid scale-up of new hepatitis C (HCV) treatments, known as interferon-free Direct Acting Antiviral (DAA) drugs, and impact on the proportion of people with HCV within the HIV-HCV coinfected population of Australia. It is hypothesised that a rapid scale-up of hepatitis C treatment with interferon-free therapies in individuals with HIV-HCV coinfection will assist in controlling HCV infection in this population.
Detailed description
This project has seven major components which will occur independently but are linked to the central theme of controlling and eliminating HCV infection from the majority of the Australian HIV positive population. Database of HIV-HCV individuals (CEASE-D): Surveillance of HIV-HCV positive individuals will occur through the enrolment into the CEASE-D observational study database. The proportion with HCV viraemia in this population will be determined through three cross-sectional surveys; at enrolment (2014-2016), follow-up 1 (2017-2018) and follow-up 2 (2019-2020). Participation will involve providing informed consent, collection of limited clinic and demographic information, a dried blood spot sample, patient completed CEASE questionnaires and FibroScan® (where available). It is estimated that approximately 1000 HIV-HCV coinfected individuals will be enrolled into the CEASE-D database. Modelling (CEASE-M): Mathematical modeling will be undertaken to examine various treatment strategies, including HCV treatment scale-up timelines. The data from the first cross-sectional survey of the HCV surveillance phase (CEASE-D) will inform components of the modeling. HCV Education for HIV prescribers (CEASE-E): A comprehensive education program in HCV treatment with interferon-free DAA therapy will be conducted with HIV prescribers with high HCV caseloads in preparation for the rapid scale-up of HCV treatment. HCV Treatment Scale-Up (CEASE-T): HCV treatment scale-up with PBS listed regimens will involve primary and tertiary clinics. All patients who are commencing HCV treatment will be invited to participate in CEASE-T which will involve data collection regarding treatment with PBS listed regimens. The regimen and duration will be determined by the treating clinician according to PBS prescribing guidelines. At selected sites subjects will be offered enrollment into a more intensive follow-up substudy (I-STEP) involving collection of research EDTA plasma samples, patient completed behavioural questionnaires and FibroScan® (where available). Patients with recurrent viraemia during or following treatment (relapse/reinfection) may also be entered into a separate substudy cohort (CEASE-V) Recurrent Viraemia Treatment (CEASE-V) At selected sites patients with on-treatment virological failure (nonresponse or viral breakthrough) or post-treatment recurrent viraemia (relapse or reinfection) will be entered into an intensive follow-up cohort (CEASE-V). Participation will involve providing informed consent, collection of research EDTA plasma samples and patient completed behavioural questionnaires. Patients may be offered retreatment with PBS listed regimens. The decision to retreat as well as the regimen and duration will be determined by the treating clinician according to PBS prescribing guidelines. Dried Blood Spot Validation Sub-study (DBS Sub-study) At selected sites patients will be invited to participate in the Dried Blood Spot Validation Sub-study (DBS Sub-study). HIV/HCV study participants and HCV control participants will be mailed DBS self-collection kits and questionnaires to evaluate feasibility, acceptability and validity of self-collected DBS samples compared to clinic collected plasma samples. Pre and post DBS acceptability questionnaires will be completed. Qualitative Sub-study (CEASE-Q) At selected sites patients will be invited to participate in the Qualitaitive Sub-study (CEASE-Q). Semi-structured interviews will be used to explore risk behaviour pre and post DAA therapy, participant experience of DAA therapy and, in untreated participants, facilitators and barriers to DAA therapy.
Interventions
None listed
Sponsors
Kirby Institute
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
CEASE-D: 1. 18 years of age or older 2. Voluntarily signed the informed consent form 3. HIV positive 4. HCV antibody positive 5. Adequate English and mental health status to provide written informed consent and comply with study procedures CEASE-T (ISTEP): 1. 18 years of age or older 2. Voluntarily signed the informed consent form 3. HIV positive 4. HCV RNA positive 5. Adequate English and mental health status to provide written informed consent and comply with study procedures 6. Undergoing DAA therapy HCV treatment. CEASE-V: 1. 18 years of age or older 2. Voluntarily signed the informed consent form 3. HIV positive 4. Undergone IFN-free DAA therapy for HCV 6\) On treatment virological failure or post-treatment recurrent viraemia as defined by either: 1. Non-response: Failure of viral suppression on IFN-free DAA therapy 2. Virological breakthrough on IFN-free DAA therapy 3. Post-treatment recurrent viraemia: Detectable HCV RNA post-treatment following an end-of-treatment response (ETR, undetectable HCV RNA at end of treatment) DBS Sub-study Population: 1\) 18 years of age or older 2) Voluntarily signed the informed consent form 3) HIV positive 4) HCV antibody positive 5) Adequate English and mental health status to provide written informed consent and comply with study procedures 6) Under follow-up within I-STEP post-treatment for HCV DBS Sub-study Controls: 1\) 18 years of age or older 2) Voluntarily signed the informed consent form 3) HIV negative 4) HCV antibody positive 5) Undergoing DAA therapy for HCV and requiring confirmation of SVR post therapy 6) Adequate English and mental health status to provide written informed consent and comply with study procedures CEASE-Q: 1\) 18 years of age or older 2) Voluntarily signed the informed consent form 3) HIV positive 4) HCV antibody positive 5) Adequate English and mental health status to provide written informed consent and comply with study procedures 6) Under follow-up within I-STEP post-treatment for HCV
Exclusion criteria
CEASE-D: 1\) Inability or willingness to comply with protocol requirements CEASE-T: 1\) Inability or willingness to comply with protocol requirements CEASE-V: 1\) Inability or willingness to comply with protocol requirements DBS Sub-study: 1\) Inability or willingness to comply with protocol requirements CEASE-Q: 1\) Inability or willingness to comply with protocol requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HCV viraemia | 5 years | Proportion of HCV viraemia within the Australian HIV-HCV population over a five year period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HCV treatment uptake | 5 years | To monitor levels and types of HCV treatment uptake over time as therapies for HCV infection evolve |
| Factors associated with HCV treatment and retreatment | 5 years | To examine factors which are associated with treatment and retreatment uptake at the tertiary, secondary and primary care level, including the influence of liver stage disease, genotype and availability of treatment regimens on treatment decision making |
| Needs, behaviour and attitudes towards HCV treatment | 5 years | To assess the needs, risk behaviour and willingness to undergo treatment in HIV-HCV coinfected individuals |
| Rates of HCV retreatment | 5 years | To monitor rates of retreatment including for treatment failure and for reinfection |
| HCV transmission history | 5 years | To characterise, using molecular epidemiology, HCV transmission history within the HIV-HCV coinfected population |
| HCV treatment response rates | 5 years | To assess treatment response rates to the roll out of interferon-free DDA therapies including the reasons for treatment failure |
Countries
Australia
Outcome results
None listed